Fong James K 4
4 · CTI BIOPHARMA CORP · Filed Jan 26, 2023
Insider Transaction Report
Form 4
Fong James K
See Remarks
Transactions
- Award
Non-Qualified Stock Option (right to buy)
2019-02-19+288,000→ 288,000 totalExercise: $0.95Exp: 2029-02-19→ Common Stock (288,000 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2023-01-24−100,000→ 188,000 totalExercise: $0.95Exp: 2029-02-19→ Common Stock (100,000 underlying) - Exercise/Conversion
common stock
2023-01-24$0.95/sh+100,000$94,890→ 103,565 total - Sale
common stock
2023-01-24$6.00/sh−100,000$600,000→ 3,565 total
Footnotes (2)
- [F1]This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
- [F2]One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.